GC Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $65M
Overview
Engineering allogeneic cell therapies for oncology using synthetic biology and AI.
Oncology
Technology Platform
Integrated platform combining synthetic biology, gene editing, and machine learning to engineer allogeneic cell therapies.
Funding History
1Total raised:$65M
Series A$65M
Opportunities
Large market opportunity in oncology if it can successfully develop safer, cheaper, and more effective off-the-shelf cell therapies.
Risk Factors
High technical and clinical risk associated with novel cell engineering and potential for immune rejection or poor persistence.
Competitive Landscape
Competes in the crowded allogeneic cell therapy arena with many companies pursuing similar technological approaches.